Answers are grounded in this paper and cite their sources.
Brazil's Constitution defines health as a right of all and a duty of the State, and the Unified Health System (SUS) translates that promise into free access to medicines at the point of care.1 Since Law 12,401/2011, new drugs enter the SUS through the National Committee for Health Technology Incorporation (CONITEC, for the acronym in Portuguese), which must weigh clinical evidence, cost-effectiveness and budget impact.2 In The Lancet Regional Health – Americas, Curado and colleagues3 step back from case-by-case appraisal and ask a system-level question: taken together, did the projected budget impacts of the 199 drugs incorporated between 2012 and 2024 add up to something the SUS could afford?
No takes yet. Share an insight, caveat, or question.
Ângelo Maiolino (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: